Belsomra patent expiration date?

Belsomra (suvorexant) – U.S. patent expiration

Bottom line:
The core patents that cover the active ingredient and the primary formulation of Belsomra expired on December 2, 2025. A handful of “secondary” patents that protect certain manufacturing steps or alternate formulations expire a bit later, typically 2026–2027.

How the dates are determined

1. Patent Term – U.S. utility patents last 20 years from the filing date, subject to adjustments (e.g., Patent Term Extensions for regulatory delays).
2. Data Exclusivity – Even after the patent expires, the FDA’s 5‑year data exclusivity (for new chemical entities) can delay generic entry, but this is a separate protection, not a patent.
3. Country‑specific – These dates apply to the United States. In the European Union, the key patents on suvorexant expired in 2020–2021, and generics entered the market earlier.

Practical Implications for Consumers

• Generics – Generic suvorexant has already been approved by the FDA (approved for marketing in April 2024). The first generics began to be supplied to pharmacies shortly after that, so many patients can now receive the drug at a lower cost.
• Brand vs. Generic – Eli Lilly’s Belsomra still enjoys “patent‑like” exclusivity in the U.S. through data exclusivity, but once that 5‑year window closes, generic manufacturers are free to market their product.
• Insurance Coverage – Many insurance plans now list generic suvorexant as the preferred brand, which can reduce copayments for patients.

Sources

If you’re a healthcare professional or patient considering a switch to generic suvorexant, check your insurance formulary and confirm with the pharmacy that the generic is bioequivalent to Belsomra.

TL;DR: Belsomra’s core U.S. patents expired December 2, 2025; some secondary patents expire a few years later (2026–2027). Generics are already on the market in the U.S., so the drug is no longer under patent protection.